

1 **Diagnostic performance of LumiraDx SARS-CoV-2 rapid antigen test compared to PCR**
2 **for diagnosis of COVID-19 in Liberia**

3
4 Moses Badio^{a,b}, Christina Lindan^b, Kumblytee Johnson^a, Cavan Reilly^c, Julie Blie^a, Katy Shaw-
5 Saliba^d, Tamba Fayiah^a, John McCullough^e, J. Tanu Duworko^a, Elizabeth Higgs^d, Jeffrey
6 Martin^b, Lisa Hensley^d

7
8 ^a Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL),
9 Monrovia, Liberia; ^b Department of Epidemiology and Biostatistics, University of California,
10 San Francisco, San Francisco, California, USA; ^c Division of Biostatistics, University of
11 Minnesota, Minneapolis, Minnesota, USA; ^d National Institute of Allergy and Infectious
12 Diseases, U.S. National Institutes of Health, Bethesda, Maryland, USA; and Advanced
13 BioMedical Laboratories, LLC, Cinnaminson, New Jersey, USA

14
15 **Corresponding author:** Moses Badio, Department of Epidemiology & Biostatistics, UCSF, 550
16 16th Street, San Francisco, California, 94158

17 **Email address:** mbadio@prevailcr.org, moses.badio@ucsf.edu

18
19 **Keywords:** Point of Care, Near Patient Testing, Virology, PCR, Nucleic Acid Amplification
20 Test, Patient Management, Antimicrobial Stewardship

21
22 **Funding:** This research was supported by the U.S. National Institutes of Health/National
23 Institute of Allergy and Infectious Disease (NIH/NIAID), Partnership for Research on Ebola

- 24 Virus in Liberia (PREVAIL); the Fogarty International Center/NIAID (U2R TW011281); and
- 25 the U.S. National Institute of Mental Health/NIH (R25 MH123256).

26 **Abstract**

27 **Background:** Diagnosis of SARS-CoV-2 infection in Liberia has primarily relied on polymerase
28 chain reaction (PCR)-based testing at the country's National Reference Laboratory. This
29 centralized approach caused reporting delays, prompting evaluation of point-of-care antigen-
30 based tests. We assessed the test performance of the LumiraDx™ SARS-CoV-2 Ag test
31 (LumiraDx™, London, UK) in this setting.

32 **Methods:** We tested ambulatory individuals screened for enrollment into an observational cohort
33 study of COVID-19 sequelae in Monrovia in 2021. We compared the results of LumiraDx
34 testing of anterior nasal swab specimens to the results of PCR BioFire® R2.1P (bioMérieux, Salt
35 Lake City, Utah) on eluent from nasopharyngeal swabs.

36 **Results:** We evaluated 348 individuals. Among the 274 persons with symptoms, 49.3% were
37 PCR-positive and 36.5% were antigen-positive. The sensitivity, specificity, negative predictive
38 value (NPV), and positive predictive value (PPV) of LumiraDx in this group were 72.6% (95%
39 CI: 64.3%-79.9%), 98.6% (95% CI: 94.9%-99.8%), 78.7% (CI: 71.9%-84.6%), and 98.0% (CI:
40 93.0%-99.8%), respectively. Among the 74 asymptomatic individuals, 12.2% were positive by
41 PCR, and 5.5% by antigen testing, resulting in a sensitivity, specificity, NPV, and PPV of
42 LumiraDx of 44.4% (95% CI: 13.7%-78.8%), 100% (95% CI: 94.5%-100%), 92.9% (CI: 84.1%-
43 97.6%), and 100% (CI: 39.8%-100%), respectively.

44 **Conclusion:** Although the specificity and PPV of LumiraDx for diagnosing SARS-CoV-2 were
45 high among persons with and without symptoms, the sensitivity was unacceptably low in both
46 groups, and much less than that reported by the manufacturer. Before new point-of-care
47 diagnostics are adopted, test performance needs to be assessed in the local setting.

48

49 **Introduction**

50 A global shortage of laboratory tests to detect SARS-CoV-2 infection occurred during the
51 beginning of the COVID-19 pandemic due to high demand and disruptions in supply chains; this
52 was particularly true in many parts of sub-Saharan Africa (SSA)[1-4]. In resource-limited
53 settings, identifying persons with COVID-19 was further complicated by the lack of alternative
54 and accurate rapid tests, causing reliance on reverse-transcriptase polymerase chain reaction
55 (PCR) to detect the presence of SARS-CoV-2 RNA. PCR technology has been the gold standard
56 for diagnosis, but requires specialized and costly equipment and reagents; processing can result
57 in lengthy delays in obtaining results[2], hindering recommendations for people to quarantine or
58 isolate, and preventing timely provision of available treatment, in turn impairing the ability to
59 reduce ongoing transmission[3]. The limitations of laboratory-based PCR testing spurred the
60 development of point-of-care (POC) rapid antigen-based diagnostics, well as self-administered
61 home-based testing[4].

62 In Liberia, laboratory-confirmed diagnosis of SARS-CoV-2 infection relied exclusively
63 on PCR testing at the National Reference Laboratory (NRL). Specimens from all 15 counties in
64 the country had to be transported to the NRL; the laboratory was difficult to access and could
65 only be reached using unpaved roads. This centralized approach caused reporting delays of at
66 least two weeks due to low throughput of the PCR platform and the logistical difficulty of
67 transporting specimens. These constraints were acutely experienced during a surge of SARS-
68 CoV-2 transmission from June to August 2021, primarily attributed to the delta-variant[5,6].
69 During this period, a large number of people with respiratory symptoms presented to health
70 facilities, but diagnosis and management of COVID-19 were impaired due to the inability to

71 obtain test results quickly. Neither POC nor self-administered home-based rapid antigen tests
72 were available in Liberia at the time.

73 The PREVAIL COVID-19 Observational Study (PCOS), a research collaboration
74 between the U.S. National Institute of Allergy and Infectious Diseases/National Institute of
75 Health (NIAID/NIH) and the Liberian Ministry of Health (MOH), was set up in August 2020 at
76 the JFK Hospital, the main referral hospital in the country. The goals of PCOS were to evaluate
77 the acute and long-term sequelae of SARS-CoV-2 infection by evaluating symptomatic and
78 asymptomatic infected individuals over time, as well as a comparator group of uninfected
79 persons. Potential participants were screened for infection using the BioFire® R2.1P
80 (bioMérieux, Salt Lake City, Utah) at the PCOS research laboratory at the JFK hospital. The
81 Liberian MOH requested assistance from PCOS to evaluate the utility and accuracy of the
82 LumiraDx™ SARS-CoV-2 antigen test (LumiraDx, London, UK). This platform was being
83 considered by the MOH for use at clinical sites around the country to hasten diagnoses and
84 reduce the burden on NRL, if it performed well in comparison to PCR. Assessment of the local
85 test performance of LumiraDx was considered important, in part because it was not known how
86 POC diagnostic tests would perform in the Liberian population, especially given early
87 indications of less severe clinical disease in many parts of SSA compared to populations in
88 Europe, South America, and the U.S.[7-9].

89 **Methods**

90 **Study design and summary**

91 We evaluated the test performance of the LumiraDx antigen test compared to the results
92 of the BioFire PCR on eluent from nasal swabs obtained from symptomatic and asymptomatic

93 individuals being screened for enrollment into PCOS. Both tests had received U.S. FDA
94 Emergency Use Authorization at the time of the study [8,9].

95 **Study population**

96 Persons of any age who were ambulatory and seeking outpatient care at the JFK Hospital
97 for any reason and who had symptoms consistent with COVID-19 were referred by clinicians to
98 the PCOS testing site for study information, testing for SARS-CoV-2, and recruitment.
99 Individuals from the community who voluntarily sought testing, regardless of symptoms, could
100 also be tested, and if interested, evaluated for enrollment. In this analysis, we present data from a
101 consecutive sample of persons who were screened from June to August 2021, regardless of
102 whether they subsequently enrolled in PCOS. All persons provided written informed consent for
103 screening procedures, and a completed a separate signed consent if they decided to enroll in
104 PCOS. The study was reviewed and approved by the Liberian National Research Ethics Board.

105 **Measurements and laboratory testing**

106 Participants completed a short interviewer-administered survey about socio-
107 demographics and whether they had experienced any of 10 COVID-19-related symptoms during
108 the last two weeks; at the time, these symptoms were included on the MOH screening algorithm
109 for COVID-19.

110 Nasopharyngeal (NP) HydraFlock swabs for PCR testing and anterior nasal HydraFlock
111 swabs for antigen testing were collected by trained laboratory technicians. Each swab was
112 rotated for 10-15 seconds in both nares. NP swabs were immediately placed in 3 mL of viral
113 transport media, and eluent tested within 45 minutes using BioFire at the PCOS research
114 laboratory co-located at JFK Hospital, following manufacturer guidelines[11]. The BioFire

115 targets the viral spike (S) and membrane (M) proteins. Anterior nasal swabs were immediately
116 placed in pre-packaged extraction buffer and tested within 30 minutes using the LumiraDx
117 instrument according to the manufacturer's instructions[12]. This test uses a microfluidic
118 immunofluorescence-based assay for the qualitative detection of the SARS-CoV-2 nucleocapsid
119 protein. Laboratory technicians wore personal protective equipment (PPE) including gowns,
120 surgical caps, masks, and gloves during specimen collection, handling, and testing; gloves were
121 changed between the processing of each individual specimen.

122 **Statistical analysis**

123 The distribution of age, gender, and symptoms were computed using proportions. We
124 determined the 'prevalence' or pre-test probability of infection in the whole sample, and among
125 persons with and without symptoms, based on the proportion with a positive BioFire PCR test.
126 We calculated the sensitivity, specificity, positive predictive value (PPV), and negative
127 predictive value (NPV) of LumiraDx with 95% confidence intervals (CI) among the entire
128 sample, as well as stratified by whether persons had symptoms or not. Based on the sensitivity
129 and specificity of the antigen test in our sample, we estimated the PPV and NPV among persons
130 with and without symptoms at varying levels of pre-test probability of SARS-CoV-2 infection.
131 Analyses were conducted using Stata version 17.0 (Stata Corporation, College Station, Texas,
132 United States).

133 **Results**

134 Among the 348 individuals evaluated, 44.3% were female; the age range was 8 to 86
135 years, and 44.3% were 30 years of age or less (Table 1). More than three-fourths (78.7%)

136 reported at least one COVID-19-related symptom in the last two weeks. The most common
137 symptoms were weakness (50.9%), cough (42.2%), body pain (37.9%), and fever (37.1%).

138 Among all NP specimens tested by BioFire, 41.4% were positive for detection of SARS-
139 CoV-2 RNA; among all anterior nasal specimens tested using LumiraDX, 29.9% were positive
140 (Table 2). Among samples from the 274 persons with symptoms, 49.3% were PCR-positive, and
141 36.5% were antigen-positive. The sensitivity, specificity, NPV and PPV of LumiraDx in this
142 group were 72.6% (95% CI: 64.3% to 79.9%), 98.6% (95% CI: 94.9% to 99.8%), 78.7% (71.9%,
143 84.6%), and 98.0% (93.0%, 99.8%) respectively. Among samples from the 74 asymptomatic
144 individuals, 12.2% were positive by PCR and 5.4% were positive by antigen-testing. The
145 sensitivity, specificity, NPV, and PPV of LumiraDx in persons without symptoms were 44.4%
146 (95% CI: 13.7% to 78.8%), 100% (95% CI: 94.5% to 100%), 92.9% (84.1%, 97.6%), and
147 100.0% (39.8%, 100%) respectively.

148 Based on our calculated sensitivity and specificity, we estimated that among persons with
149 symptoms, the PPV of LumiraDx would be $\geq 90\%$ when the true prevalence of infection is
150 15% or higher (Figure). In symptomatic persons, the NPV increases as the prior-probability of
151 infection, decreases, reaching $\geq 90\%$ when the true prevalence is 30% or less. Among
152 asymptomatic persons, the NPV would be high, or $\geq 90\%$, when the true prevalence of
153 infection is 16% or less. The PPV among asymptomatic individuals at varying levels of
154 prevalence could not be calculated, however, because the specificity was 100%.

155 **Discussion**

156 We evaluated the test performance of the LumiraDx SARS-CoV-2 Ag test compared to
157 the BioFire PCR in Liberia and found that among persons both with and without symptoms, the

158 antigen test had a high specificity and PPV of 98% -100%. In contrast, the sensitivity was
159 unacceptably low: 73% in persons with symptoms, and 44% among asymptomatic people. This
160 means that in someone presenting with symptoms suggestive of COVID-19, a negative test
161 would need to be corroborated by a PCR or other nucleic acid amplification test (NAAT),
162 particularly at higher levels of community prevalence. Because of these findings, the Liberian
163 MOH decided not provide LumiraDx to local hospitals and clinics as an alternative decentralized
164 method of diagnosing infections.

165 The sensitivity of LumiraDx that we found in our Liberian sample was substantially
166 different from the 97.6% presented in the manufacturer's insert [13] and a publication based on
167 the same data [14]. It should be noted that the the product insert and the paper by Drain et al, do
168 not specify the symptom status of those tested using anterior nasal swabs, or how participants
169 were selected. Even if we assume all persons in those studies were symptomatic, the 73%
170 sensitivity we found among persons with symptoms was still much lower in the product insert. It
171 is possible that individuals in the manufacturer's study had more severe COVID-19 disease
172 compared to our participants, with a higher viral load and thereby more likely to be detected by
173 an antigen test [13,14].

174 Several published studies have also evaluated the performance of LumiraDx compared to
175 PCR as the gold standard. Similar to our findings, most found a high specificity among both
176 symptomatic and asymptomatic individuals [15-18]. Reported sensitivity varied widely, however.
177 Some studies found sensitivities of 90% or greater [15,17,18], while others reported values closer
178 to the 73% we observed [19,16,20]. It is worth noting that studies reporting a high sensitivity
179 primarily tested patients in emergency departments or residents of nursing homes, who might
180 have been sicker than our participants [15,18,17]. Studies that found a lower sensitivity generally

181 evaluated individuals seeking care at outpatient departments, who may have been more similar
182 our ambulatory sample [19,21].

183 The variability in test performance among studies and by patient population, highlights
184 the importance of evaluating test diagnostics in the population and setting in which they are to be
185 used. In addition, the probability that a negative or a positive test finding is accurate depends on
186 the probability of true infection among persons being tested, which varies across geographic
187 regions, and is another reason to determine the accuracy of a test where it will be used. It should
188 be noted that the only other study from SSA that evaluated LumiraDx in addition to ours was
189 performed in Mozambique, and found similarly low sensitivity as in our study, or 80% among
190 those with symptoms, and 48% among those who were asymptomatic[21].

191 We do not believe that the low sensitivity we found was due to laboratory or other
192 procedural errors. The on-site research laboratory used for many other PREVAIL studies in
193 addition to PCOS, conducts verification and validation testing to ensure the accuracy and
194 reliability of findings. However, our study did have several limitations. First, the sample size for
195 asymptomatic individuals was small, resulting in wide confidence intervals around some
196 estimates. Secondly, the manufacturer recommends that LumiraDx not be used more than 12
197 days after symptom onset. We did not collect information about when symptoms began;
198 therefore, it is possible that the low sensitivity and NPV among symptomatic participants could
199 partially be a results of including persons beyond the window of detection for the LumiraDx.
200 Finally, we only asked participants about 10 possible COVID-19 related symptoms. Since then,
201 many additional symptoms have been associated with acute SARS-CoV-2 infection [24].
202 Misclassifying some persons with COVID-19 symptoms that we did not recognize, could have
203 resulted in us calculating a somewhat falsely low NPV.

204 The LumiraDx platform could be a useful test to quickly triage persons with a positive
205 antigen test in clinical and resource limited settings when confirmatory NAAT testing is not
206 rapidly available or affordable [22-24]. The turnaround time to obtain a test result once the
207 sample has been inserted into the machine, is only 12 minutes, and use of the platform does not
208 required skilled technicians. The main logistical drawbacks are that the platform needs to be used
209 in a laboratory setting, and only one sample can be evaluated at a time. Despite the several
210 advantages of the LumiraDx diagnostic test, however, the low NPV means that a negative result
211 in someone with symptoms can not be used to rule-out an infection, requiring a confirmatory
212 test.

213 Our study demonstrated both the potential usefulness and limitations of using this antigen
214 test in a country in west Africa, and highlighted the importance of not assuming published test
215 performance is applicable across regions and different populations. The COVID-19 pandemic
216 has waned, and the urgency of alternative screening and testing methods for SARS-CoV-2
217 infection is no longer acute. During the last several years, home-based and self-administered
218 testing using convenient and rapid lateral flow tests have been widely used in many parts of the
219 world. Unfortunately, they have never become available in Liberia. Nevertheless, transmission
220 of infections has steadily declined in Liberia similar to other countries[6], likely due to a
221 combination of immunity from infection and vaccination, and circulation of less virulent
222 variants. Despite the present reduced threat from this infection, the initial severe and highly
223 disruptive impact of the SARS-CoV-2 pandemic warns us of the potential spread and
224 consequences of a pathogen against which the global community is unprepared, and the need to
225 assess novel diagnostic tools, particularly for new pathogens, in the population in which they will

226 be used. The scientific and public health community should not assume validated tests will
227 perform similarly in different populations.

228

229

230 **Acknowledgements**

231 We thank staff at the Ministry of Health, Liberia and JKF Medical Center for their
232 collaboration in making this study possible. We would also like to acknowledge the contribution
233 of the PCOS study team for implementing the study, and the laboratory staff for conducting the
234 testing. We also gratefully acknowledge all the participants.

235

236 **Authors' Declarations**

237 All named authors have seen and agreed to the submitted version of the paper. The material
238 is original and is unpublished in another journal; it not currently being submitted elsewhere for
239 publication. Preliminary information from the study was presented as an abstract at the
240 International Conference of the West African Consortium.

241 **Declaration of Competing Interest**

242 The authors declare no conflicts of interest.

243

244

245 **Author Contributions**

246 **Moses Badio:** Conceptualization, Data curation, Formal analysis, Investigation, Methodology,
247 Project administration, Supervision, Visualization, Writing – original draft, Writing – review &
248 editing. **Christina Lindan:** Funding acquisition for analysis and writing, Methodology of
249 analysis, Supervision, Visualization, Writing – original draft, Writing – review & editing.
250 **Kumblytee Johnson:** Conceptualization, Data curation, Investigation, Methodology, Project
251 administration, Resources, Supervision, Writing – review & editing. **Cavan Reilly:**
252 Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Visualization,
253 Writing – review & editing. **Julie Blie:** Validation, Data curation, Project administration,
254 Supervision. **Katy Saliba:** Validation, Project administration, Resources, Supervision, Writing –
255 review & editing. **Tamba Fayiah:** Data curation, Writing – review & editing. **John**
256 **McCullough:** Validation, Data curation, Project administration, Supervision. **James Duworko:**
257 Funding acquisition, Project administration, Resources, Supervision, Writing – review & editing.
258 **Elizabeth Higgs:** Conceptualization, Funding acquisition, Investigation, Methodology,
259 Resources, Supervision, Writing – review & editing. **Jeff Martin:** Funding acquisition,
260 Methodology, Resources, Supervision, Visualization, Writing – original draft, Writing – review
261 & editing. **Lisa Hensley:** Conceptualization, Funding acquisition, Investigation, Methodology,
262 Resources, Supervision, Visualization, Writing – review & editing.

263 **Table 1. Demographic characteristics and symptoms of participants tested for SARS-CoV-2 infection**
264 **with LumiraDx™ antigen test and BioFire® PCR, Monrovia, Liberia, June – August 2021**

	N	%
All	348	100
Age¹, years		
≤30	152	44.3%
31-50	63	18.4%
>50	128	37.3%
Female	154	44.3%
Symptomatic		
Any symptom	274	78.7%
Symptoms²		
Fever	129	37.1%
Cough	147	42.2%
Sneezing	56	16.1%
Sore throat	40	11.5%
Shortness of breath	121	34.8%
Absence of smell	66	19.0%
Weakness/fatigue	177	50.9%
Body pain	132	37.9%
Headache	123	35.3%
Diarrhea	33	9.5%


265 ¹Small differences in N are due to missing data

266 ²Only among the 274 who had at least one symptom

267 **Table 2. LumiraDx™ SARS-CoV-2 antigen test performance compared to BioFire® R2.1P PCR among**
 268 **persons with and without COVID-19 symptoms, Monrovia, Liberia, June – August 2021**

BioFire						
LumiraDx	Positive	Negative	All	LumiraDx test performance	%	(95% CI)
All				Sensitivity	70.8%	[62.7%, 78.1%]
Positive	102	2	104	Specificity	99.0%	[96.5%, 99.9%]
Negative	42	202	244	Positive predictive value	98.1%	[93.2%, 99.8%]
Total	144	204	348	Negative predictive value	82.8%	[77.5%, 87.3%]
Symptomatic				Sensitivity	72.6%	[64.3%, 79.9%]
Positive	98	2	100	Specificity	98.6%	[94.9%, 99.8%]
Negative	37	137	174	Positive predictive value	98.0%	[93.0%, 99.8%]
Total	135	139	274	Negative predictive value	78.7%	[71.9%, 84.6%]
Asymptomatic				Sensitivity	44.4%	[13.7%, 78.8%]
Positive	4	0	4	Specificity	100.0%	[94.5%, 100%]
Negative	5	65	70	Positive predictive value	100.0%	[39.8%, 100%]
Total	9	65	74	Negative predictive value	92.9%	[84.1%, 97.6%]

269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283



284

285 **Figure 1. Predictive value of the LumiraDx™ antigen test in populations with varying prevalence of**
286 **acute SARS-CoV-2 infection, among symptomatic and asymptomatic individuals.**

287 Note: The specificity among asymptomatic individuals is 100%. Hence, the PPV cannot be calculated.

288 **References**

- 289 [1] A. Babiker, C. W. Myers, C. E. Hill, and J. Guarner, “SARS-CoV-2 Testing Trials and
290 Tribulations,” *Am. J. Clin. Pathol.*, vol. 153, no. 6, pp. 706–708, May 2020, doi:
291 10.1093/AJCP/AQAA052.
- 292 [2] N. R. Blumenfeld *et al.*, “Multiplexed reverse-transcriptase quantitative polymerase chain
293 reaction using plasmonic nanoparticles for point-of-care COVID-19 diagnosis,” *Nat.*
294 *Nanotechnol.*, Jul. 2022, doi: 10.1038/S41565-022-01175-4.
- 295 [3] D. B. Larremore *et al.*, “Test sensitivity is secondary to frequency and turnaround time for
296 COVID-19 surveillance,” *medRxiv Prepr. Serv. Heal. Sci.*, Sep. 2020, doi:
297 10.1101/2020.06.22.20136309.
- 298 [4] K. S. Liu, X. D. Mao, W. Ni, and T. P. Li, “Laboratory detection of SARS-CoV-2: A
299 review of the current literature and future perspectives,” *Heliyon*, vol. 8, no. 10, p. e10858,
300 Oct. 2022, doi: 10.1016/J.HELIYON.2022.E10858.
- 301 [5] B. Shobayo *et al.*, “SARS-CoV-2 Sequence Analysis during COVID-19 Case Surge,
302 Liberia, 2021,” *Emerg. Infect. Dis.*, vol. 27, no. 12, pp. 3185–3188, Dec. 2021, doi:
303 10.3201/EID2712.211818.
- 304 [6] “Liberia: WHO Coronavirus Disease (COVID-19) Dashboard With Vaccination Data |
305 WHO Coronavirus (COVID-19) Dashboard With Vaccination Data.”
306 <https://covid19.who.int/region/afro/country/lr> (accessed June. 7, 2023).
- 307 [7] O. O. Oleribe, A. A. A. Suliman, S. D. Taylor-Robinson, and T. Corrah, “Possible
308 Reasons Why Sub-Saharan Africa Experienced a Less Severe COVID-19 Pandemic in
309 2020,” *J. Multidiscip. Healthc.*, vol. 14, pp. 3267–3271, Dec. 2021, doi:
310 10.2147/JMDH.S331847.
- 311 [8] A. Kalungi, E. Kinyanda, D. H. Akena, P. Kaleebu, and I. M. Bisangwa, “Less Severe
312 Cases of COVID-19 in Sub-Saharan Africa: Could Co-infection or a Recent History of
313 Plasmodium falciparum Infection Be Protective?,” *Front. Immunol.*, vol. 12, p. 565625,
314 2021, doi: 10.3389/fimmu.2021.565625.
- 315 [9] FDA, “BioFire COVID-19 Test - Letter of Authorization,” 2023.

- 316 [10] FDA, “LumiraDx SARS-CoV-2 RNA STAR Complete - Letter of Authorization,” 2023,
317 <https://www.fda.gov/media/152406/download>, (accessed June 07, 2023).
- 318 [11] “Respiratory Pathogen Panel Test | BioFire Diagnostics.”
319 <https://www.biofire.com/products/the-filmarray-panels/filmarrayrp/> (accessed June 07,
320 2023).
- 321 [12] “COVID-19 SARS-CoV-2 Antigen Test | LumiraDx.” [https://www.lumiradx.com/us-](https://www.lumiradx.com/us-en/test-menu/antigen-test)
322 [en/test-menu/antigen-test](https://www.lumiradx.com/us-en/test-menu/antigen-test) (accessed June 07, 2023).
- 323 [13] “LumiraDx SARS-CoV-2 Ag Test,” Feb. 2022.
324 [https://www.lumiradx.com/assets/pdfs/covid-19-antigen-test/sars-cov-2-antigen-product-](https://www.lumiradx.com/assets/pdfs/covid-19-antigen-test/sars-cov-2-antigen-product-insert/sars-cov-2-ag-test-strip-product-insert-eua.pdf?v=8)
325 [insert/sars-cov-2-ag-test-strip-product-insert-eua.pdf?v=8](https://www.lumiradx.com/assets/pdfs/covid-19-antigen-test/sars-cov-2-antigen-product-insert/sars-cov-2-ag-test-strip-product-insert-eua.pdf?v=8), (accessed: June 07, 2023).
- 326 [14] P. K. Drain *et al.*, “A Rapid, High-Sensitivity SARS-CoV-2 Nucleocapsid Immunoassay
327 to Aid Diagnosis of Acute COVID-19 at the Point of Care: A Clinical Performance
328 Study,” *Infect. Dis. Ther.*, vol. 10, no. 2, 2021, doi: 10.1007/s40121-021-00413-x.
- 329 [15] J. Fajnzylber *et al.*, “SARS-CoV-2 viral load is associated with increased disease severity
330 and mortality,” *Nat. Commun.*, vol. 11, no. 1, p. 5493, 2020, doi: 10.1038/s41467-020-
331 19057-5.
- 332 [16] F. Yu *et al.*, “Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected
333 Patients,” *Clin. Infect. Dis.*, vol. 71, no. 15, pp. 793–798, Jul. 2020, doi:
334 10.1093/cid/ciaa345.
- 335 [17] M. Domínguez Fernández, A. Seoane Estévez, F. Lamelo Alfonsín, and G. Bou,
336 “Usefulness of the LumiradxTM SARS-COV-2 antigen test in nursing home.,”
337 *Enfermedades infecciosas y microbiología clínica (English ed.)*, vol. 40, no. 7. Spain, pp.
338 404–405, 2022. doi: 10.1016/j.eimce.2022.04.008.
- 339 [18] L. J. Krüger *et al.*, “Evaluation of accuracy, exclusivity, limit-of-detection and ease-of-use
340 of LumiraDxTM: An antigen-detecting point-of-care device for SARS-CoV-2,” *Infection*,
341 2021, doi: 10.1007/s15010-021-01681-y.
- 342 [19] E. Burdino *et al.*, “SARS-CoV-2 microfluidic antigen point-of-care testing in Emergency
343 Room patients during COVID-19 pandemic.,” *J. Virol. Methods*, vol. 299, p. 114337, Jan.

- 344 2022, doi: 10.1016/j.jviromet.2021.114337.
- 345 [20] J. E. Ellis, P. Guest, V. Lawson, J. Loecherbach, N. Lindner, and A. McCulloch,
346 “Performance Evaluation of the Microfluidic Antigen LumiraDx SARS-CoV-2 and
347 Flu A/B Test in Diagnosing COVID-19 and Influenza in Patients with Respiratory
348 Symptoms.,” *Infect. Dis. Ther.*, vol. 11, no. 6, pp. 2099–2109, Dec. 2022, doi:
349 10.1007/s40121-022-00696-8.
- 350 [21] N. Siteo *et al.*, “Clinical Performance of Self-Collected Nasal Swabs and Antigen Rapid
351 Tests for SARS-CoV-2 Detection in Resource-Poor Settings.,” *Biomedicines*, vol. 10, no.
352 9, Sep. 2022, doi: 10.3390/biomedicines10092327.
- 353 [22] M. Micocci *et al.*, “Point of care testing using rapid automated antigen testing for SARS-
354 COV-2 in care homes – an exploratory safety, usability and diagnostic agreement
355 evaluation,” *J. Patient Saf. Risk Manag.*, vol. 26, no. 6, 2021, doi:
356 10.1177/25160435211054207.
- 357 [23] L. J. Krüger *et al.*, “Evaluation of accuracy, exclusivity, limit-of-detection and ease-of-use
358 of LumiraDx™: An antigen-detecting point-of-care device for SARS-CoV-2.,” *Infection*,
359 vol. 50, no. 2, pp. 395–406, Apr. 2022, doi: 10.1007/s15010-021-01681-y.
- 360 [24] C. Chakraborty, A. R. Sharma, G. Sharma, M. Bhattacharya, and S. S. Lee, “SARS-CoV-
361 2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and
362 proposed therapeutic options.,” *Eur. Rev. Med. Pharmacol. Sci.*, vol. 24, no. 7, pp. 4016–
363 4026, Apr. 2020, doi: 10.26355/eurrev_202004_20871.
- 364 [25] Z. Duma, V. Ramsuran, A. A. Chuturgoon, V. A. Edward, P. Naidoo, and Z. L. Mkhize-
365 Kwitshana, “Evaluation of Various Alternative Economical and High Throughput SARS-
366 CoV-2 Testing Methods within Resource-Limited Settings,” *International Journal of*
367 *Molecular Sciences*, vol. 23, no. 22. 2022. doi: 10.3390/ijms232214350.
- 368 [26] Z. Duma *et al.*, “The challenges of severe acute respiratory syndrome coronavirus 2
369 (SARS-CoV-2) testing in low-middle income countries and possible cost-effective
370 measures in resource-limited settings,” *Global. Health*, vol. 18, no. 1, p. 5, 2022, doi:
371 10.1186/s12992-022-00796-7.